Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 250

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 250
---
 an underwritten public offering for aggregate gross proceeds of $ 3.5million and net proceeds of $ 2.9million. See note 8d (iii).

On September 18, 2023, the Company completed an underwritten public offering for aggregate gross proceeds of $ 2.25million and net proceeds of $ 1.8million. See note 8d (viii).

On January 16, 2024, the Company completed a registered direct and private placement for aggregate gross proceeds of $ 2.40million. See note 8b (iii).

| b. | Going concern |

These consolidated financial statements have been prepared
on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal
course of business. For the year ended October 31, 2024, the Company did not generate any revenues and had negative cash flow from operations
of $. As of October 31, 2024, the Company had an accumulated deficit of $. The continued operations of the Company
are dependent on its ability to generate future cash flows or obtain additional financing through debt or equity. Management is of the
opinion that sufficient working capital will be obtained from external financing to meet the Company’s liabilities and commitments
as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable
to the Company. These factors raise substantial doubt on the Company’s ability to continue as a going concern. These consolidated
financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.

| c. | Reverse share split |

On September 30, 2022, the Company’s Board of Directors (the “Board”) approved a 1-for-30 reverse split of its issued and outstanding common shares, effective as of September 30, 2022, pursuant to which holders of the Company’s common shares received 0.0333of a common share for every onecommon share.

On November 28, 2023, the Board approved a 1-for-30 reverse split of its issued and outstanding common shares, effective as of November 28, 2023, pursuant to which holders of the Company’s common shares received 0.0333of a common share for every onecommon share then held.

All issued and outstanding common shares or instruments convertible into common shares contained in these financial statements have been retroactively adjusted to